Abstract
Purpose
Materials and Methods
Results
ACKNOWLEDGEMENTS
Notes
AUTHOR CONTRIBUTIONS:
Conceptualization: Chul Kyu Roh, Yoon Young Choi, Jae-Ho Cheong.
Data curation: Chul Kyu Roh, Yoon Young Choi, Seohee Choi, Won Jun Seo, Minah Cho, Taeil Son, Hyoung-Il Kim, Woo Jin Hyung, Sung Hoon Noh, Jae-Ho Cheong.
Formal analysis: Chul Kyu Roh, Yoon Young Choi.
Funding acquisition: Sung Hoon Noh, Jae-Ho Cheong.
Investigation: Chul Kyu Roh, Yoon Young Choi, Seohee Choi, Won Jun Seo, Minah Cho, Taeil Son, Hyoung-Il Kim, Woo Jin Hyung, Sung Hoon Noh, Jae-Ho Cheong.
Methodology: Yoon Young Choi, Eunji Jang, Hyeseon Kim.
Project administration: Yong-Min Huh, Jae-Ho Cheong.
Resources: Chul Kyu Roh, Yoon Young Choi, Seohee Choi, Won Jun Seo, Minah Cho, Taeil Son, Hyoung-Il Kim, Woo Jin Hyung, Sung Hoon Noh, Jae-Ho Cheong.
Software: Chul Kyu Roh, Yoon Young Choi, Eunji Jang, Hyeseon Kim.
Supervision: Jae-Ho Cheong.
Validation: Chul Kyu Roh, Yoon Young Choi, Seohee Choi, Won Jun Seo, Minah Cho, Taeil Son, Hyoung-Il Kim, Woo Jin Hyung, Sung Hoon Noh, Jae-Ho Cheong.
Visualization: Chul Kyu Roh, Yoon Young Choi.
Writing—original draft: Chul Kyu Roh, Yoon Young Choi, Eunji Jang.
Writing—review & editing: Jae-Ho Cheong.
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Fig. 1
Kaplan-Meier and log-rank comparisons of DFS in patients with stage II/III gastric cancer according to (A) status of MSI and SPC-prognosis, (B) status of EBV and SPC-prognosis, (C) EBV status and treatment. DFS, disease-free survival; MSI, microsatellite instability; SPC, single patient classifier; MSS, microsatellite stable; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-high; EBV, Epstein-Barr virus; CTx, adjuvant chemotherapy (capecitabine plus oxaliplatin).
![ymj-60-132-g001](/upload/SynapseXML/0069ymj/thumb/ymj-60-132-g001.jpg)
Fig. 2
Kaplan-Meier and log-rank comparisons of DFS in patients with stage II/III gastric cancer following treatment in subgroups of (A) MSS/MSI-L and SPC responder group, (B) MSS/MSI-L and SPC non-responder group, (C) EBV-negative and SPC responder group, and (D) EBV-negative and SPC non-responder group. DFS, disease-free survival; CTx, adjuvant chemotherapy (capecitabine plus oxaliplatin); MSS, microsatellite stable; MSI-L, microsatellite instability-low; SPC, single patient classifier; EBV, Epstein-Barr virus.
![ymj-60-132-g002](/upload/SynapseXML/0069ymj/thumb/ymj-60-132-g002.jpg)
Table 1
Clinical Characteristics of Entire Cohort
![ymj-60-132-i001](/upload/SynapseXML/0069ymj/thumb/ymj-60-132-i001.jpg)
EBV, Epstein-Barr virus; MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-high; CTx, adjuvant chemotherapy (capecitabine plus oxaliplatin); SPC, single patient classifier.
Data are expressed as mean±standard deviation or as n (%).
*According to American Joint Committee on Cancer 6th edition.
Table 2
Clinical Characteristics of Patients according to EBV Status
![ymj-60-132-i002](/upload/SynapseXML/0069ymj/thumb/ymj-60-132-i002.jpg)
Table 3
Associations between SPC, MSI, and EBV Status
![ymj-60-132-i003](/upload/SynapseXML/0069ymj/thumb/ymj-60-132-i003.jpg)
Table 4
Disease-Free Survival Analyzed by a Multivariate Cox Proportional-Hazards Model
![ymj-60-132-i004](/upload/SynapseXML/0069ymj/thumb/ymj-60-132-i004.jpg)
HR, hazard ratio; CI, confidence interval; CTx, adjuvant chemotherapy (capecitabine plus oxaliplatin); SPC, single patient classifier; MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, microsatellite instability-low; MSI-H, microsatellite instability-high.
*According to American Joint Committee on Cancer 6th edition.